MedTrace Logo

Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia

NCT01279213 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2011-01-19

No results posted yet for this study

Summary

augmentation of clozapine with paliperidone in the treatment of resistant schizophrenia has not been tested until now in randomized controlled trials. This combination is supposed to have therapeutic efficacy in the treatment of resistant schizophrenia.

Conditions

Interventions

DRUG

paliperidone clozapine

dose 3 to 12 mg paliperidone ER daily during 12 weeks

Sponsors & Collaborators

  • Universidad Nacional de Rosario

    lead OTHER

Principal Investigators

  • daniel j serrani azcurra, MD · faculty of psychology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-10-31
Completion
2009-12-31

Countries

  • Argentina

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01279213 on ClinicalTrials.gov